Nuclear factor erythroid 2-related factor 2 (NRF2) is a master transcriptional regulator of genes whose products defend our cells for toxic and oxidative insults. Although NRF2 activation may reduce cancer risk by suppressing oxidative stress and tumor-promoting inflammation, many cancers exhibit elevated NRF2 activity either due to mutations that disrupt the negative control of NRF2 activity or other factors. Importantly, NRF2 activation is associated with poor prognosis and NRF2 has turned out to be a key activator of cancer-supportive anabolic metabolism. In this review, we summarize the diverse roles played by NRF2 in cancer focusing on metabolic reprogramming and tumor-promoting inflammation.
Dylan G. Ryan, Elena V. Knatko, Alva M. Casey, Jens Hukelmann, Alejandro J. Brenes, Sharadha Dayalan Naidu, Maureen Higgins, Laura Tronci, Efterpi Nikitopoulou, Luke O'neill, Christian Frezza, Angus I. Lamond, Andrey Y. Abramov, Doreen A. Cantrell, Michael P. Murphy, Albena T. Dinkova‐Kostova
Dylan G. Ryan, Elena V. Knatko, Alva M. Casey, Jens Hukelmann, Alejandro J. Brenes, Sharadha Dayalan Naidu, Maureen Higgins, Laura Tronci, Efterpi Nikitopoulou, Luke O'neill, Christian Frezza, Angus I. Lamond, Andrey Y. Abramov, Doreen A. Cantrell, Michael P. Murphy, Albena T. Dinkova‐Kostova
Dylan G. Ryan, Elena V. Knatko, Alva M. Casey, Jens Hukelmann, Sharadha Dayalan Naidu, Alejandro J. Brenes, Thanapon Ekkunagul, Christa P. Baker, Maureen Higgins, Laura Tronci, Efterpi Nikitopolou, Tadashi Honda, Richard C. Hartley, Luke O'neill, Christian Frezza, Angus I. Lamond, Andrey Y. Abramov, J. Simon C. Arthur, Doreen A. Cantrell, Michael P. Murphy, Albena T. Dinkova‐Kostova
Discussion(0)
No comments yet. Be the first to comment.